Generic Overactive Bladder Drugs Receive FDA Approval

Glenmark Pharmaceuticals and Alembic Pharmaceuticals have both received FDA approval for generic Solifenacin Succinate Tablets, 5 mg and 10 mg, a therapeutic equivalent to Astellas’ Vesicare Tablets, 5 mg and 10 mg.1,2

Glenmark and Alembic are among a small handful of companies, including Teva, working to produce this medication.1-3

Solifenacin succinate tablet is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.1

In the United States, solifenacin succinate tablets, 5 mg and 10 mg have an estimated market size of $927-967 million for 12 months ending December 2018 according to IQVIA.1-3

According to Alembic, the company has a total of 94 Abbreviated New Drug Application (ANDA) approvals, including 82 final approvals and 12 tentative approvals, from the FDA.1

Glenmark’s current portfolio consists of 154 products authorized for distribution in the United States and 58 ANDAs pending approval with the FDA.2

Teva announced in April the launching of its version of solifenacin succinate Tablets, 5 mg and 10 mg.3

  1. Alembic Pharmaceuticals receives USFDA Approval for Solifenacin Succinate Tablets, 5 mg and 10 mg [news release]. Vadodara, India; May 21, 2019: Alembic. Accessed May 21, 2019.
  2. Glenmark Pharmaceuticals receives ANDA approval for Solifenacin Succinate Tablets, 5 mg and 10 mg [news release]. Mumbai, India; May 21, 2019: Glenmark. Accessed May 21, 2019.
  3. Teva Announces Launch of a Generic Version of VESIcare® (solifenacin succinate) Tablets in the United States [news release]. Jerusalem; April 22, 2019: Teva. Accessed May 21, 2019.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

The drug, onasemnogene abeparvovec-xioi (Zolgensma, AveXis), is an adeno-associated virus vector-based gene therapy that targets the cause of SMA, a leading genetic cause of infant mortality.
The sNDA was granted Priority Review and accepted under the agency's Real-Time Oncology Review pilot program, which aims to make the review of oncology drugs more efficient by allowing the FDA access to clinical trial data before the information is formally submitted to the agency.
The drug application was granted the FDA’s Priority Review designation, as well as a Tropical Disease Priority Review Voucher under a program intended to encourage development of new drugs and biologics for the prevention and treatment of certain tropical diseases.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.